Amplify Weight Loss Drug & Treatment ETF (THNR) Price, Holdings, & News

ETF Overview

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

Key Stats

• Today's Range: $21.66 to $21.66
• 50-Day Range: $18.85 to $22.76
• 52-Week Range: $18.56 to $28.19
• Volume: 100 shs
• Average Volume: 3,261 shs
• Market Capitalization: $2.82 million
• Assets Under Management: $2.86 million
• Dividend Yield: 1.02%
• Net Expense Ratio: 0.59%
• Aggregate Rating: Moderate Buy

THNR ETF - Frequently Asked Questions

How have THNR shares performed this year?

Amplify Weight Loss Drug & Treatment ETF's stock was trading at $22.55 at the start of the year. Since then, THNR shares have decreased by 3.9% and is now trading at $21.66.
View the best growth stocks for 2025 here.

Who are Amplify Weight Loss Drug & Treatment ETF's major shareholders?

Amplify Weight Loss Drug & Treatment ETF's top institutional investors include Jane Street Group LLC (19.15%) and Harbour Investments Inc. (3.79%).

How do I buy shares of Amplify Weight Loss Drug & Treatment ETF?

Shares of THNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amplify Weight Loss Drug & Treatment ETF own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amplify Weight Loss Drug & Treatment ETF investors own include Archer Aviation (ACHR), Advanced Micro Devices (AMD), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Lockheed Martin (LMT), NICE (NICE) and Intellia Therapeutics (NTLA).

Fund Details

• Issuer: Amplify
• Fund Name: Amplify Weight Loss Drug & Treatment ETF
• Tax Classification: Regulated Investment Company
• Stock Exchange: NYSEARCA
• Current Symbol: NYSEARCA:THNR
• Inception Date: 5/21/2024
• Fund Manager: Dustin Lewellyn, Ernesto Tong, Anand Desai
• Web: N/A
• Phone: N/A

Fund Focus

• Asset Class: Equity
• Benchmark: N/A
• Category: Strategy
• Focus: Theme
• Development Level: Developed Markets
• Region: Global
• Number of Holdings: 26

Fund Statistics

• Assets Under Management: $2.86 million
• Average Daily Volume: $0.00
• Discount/Premium: 0.03%

Administrator, Advisor and Custodian

• Administrator: U.S. Bancorp Fund Services, LLC
• Advisor: Amplify Investments LLC
• Custodian: U.S. Bank, N.A.
• Distributor: Foreside Fund Services, LLC
• Transfer Agent: U.S. Bancorp Fund Services, LLC
• Trustee: N/A
• Lead Market Maker: GTS

Options

• Optionable: N/A
• Short Interest: 200 shs

Miscellaneous

• Outstanding Shares: 130,000
• Beta: N/A
• Creation Unit: 10,000
• Creation Fee: $300.00